Abstract
Esophagogastric junction (EGJ) adenocarcinoma represents 27% of gastric tumors with an increasing incidence in Western countries. Additionally, up to 80% of EGJ tumors are diagnosed in advanced stages of disease, therefore the prognosis is usually poor, with a 5-year overall survival rate of less than 30%. It is known that EGJ tumors are an entity with its own epidemiological characteristics, biological behavior, and prognosis, without evidence to support optimal management. The aim of this study was to describe clinicopathological features, treatment, and outcome of Latin American patients with EGJ adenocarcinoma treated at the National Cancer Institute.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
